Journal article
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Abstract
The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients participated in randomized comparisons of (1) doxorubicin given with or without dexrazoxane, a cardioprotectant (high-risk patients), (2) intensive intrathecal chemotherapy and cranial radiation (standard-risk patients), and (3) Erwinia …
Authors
Moghrabi A; Levy DE; Asselin B; Barr R; Clavell L; Hurwitz C; Samson Y; Schorin M; Dalton VK; Lipshultz SE
Journal
Blood, Vol. 109, No. 3, pp. 896–904
Publisher
American Society of Hematology
Publication Date
February 1, 2007
DOI
10.1182/blood-2006-06-027714
ISSN
0006-4971